Trifluoroperazine for the symptomatic treatment of chorea.
Ten consecutive patients with chorea of different etiologies were treated with trifluoroperazine, 7 were adults and 3 children; all the patients received symptomatic benefit from the medication, the effective dose ranged from 4 to 16 milligrams. The medication was well tolerated and proved to be effective a long period of time. Biochemical and pathophysiological aspects of chorea and its relations to the medication are discussed.
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D002561:Cerebrovascular Disorders / Q000150:complications; D002648:Child; D002819:Chorea / Q000188:drug therapy* / Q000209:etiology; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D013577:Syndrome; D013997:Time Factors; D014268:Trifluoperazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced
D014268:Trifluoperazine